Agenda
| 9:00 AM - 9:30 AM |
Registration & Networking |
9:30 AM - 10:30 AM |
Presentation & Q&A |
10:40 AM - 11:30 AM |
BioCenter Tour |
11:30 AM - 12:30 PM |
Lunch & Networking |
12:30 PM - 5:00 PM |
One-on-one Meetings |
Emerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the “Meet with…” Series, we provide emerging companies with greater access to partnering and/or financing opportunities.
In this session, Directors from
Gilead will talk to potential licensees to first explain what they are looking for in a company. After the presentation, attendees will have lunch with the Gilead team.
Finally,
each pre-approved attendee* will be granted a private meeting with
Shehnaaz Suliman, M.D., Senior Director of Corporate Development at Gilead Sciences - or
Sean OConnell, Senior Director of Business Development at Gilead Sciences.
*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by May 28, 2010 to events@sjbiocenter.com. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on June 4, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.
Please visit our dedicated page for more information about the Meet with... Series»
One-on-one Meeting Application & Costs
• Application fee: FREE
• Registration for one company representative:
o $175 Regular
o $150 Partners’ Network
• Registration for two company representatives:
o $250 Regular
o $215 Partners’ Network
• Registration for three company representatives:
o $300 Regular
o $255 Partners’ Network
• Registration for four company representatives and above:
o add $40 [or $30 for Partners’ Network] per attendee
• BioCenter Residents and Affiliates: Free
Presentation & Q&A Costs**
• Regular Price: $40
• Partners' Network: $30
• BioCenter Members: Free (please RSVP to Aurélie)
**Includes: Presentation & Q&A session + lunch ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! Additionally, there will be no on-site registrations.
About Gilead's areas of interest
Scientific breakthrough is almost always the product of collaboration and Gilead places high value on partnering with companies and organizations whose strengths complement and augment our own. Over the past two decades, we have forged many long-term collaborations with leading academic institutions and biotechnology and pharmaceutical companies to develop innovative new therapeutics and advance the care of patients confronting life-threatening diseases.
Speakers Bios
Shehnaaz Suliman, M.D., Senior Director, Corporate Development, Gilead Sciences
Since joining Gilead’s Corporate Development Group in 2004, Shehnaaz has played a key role in evaluating in-licensing and merger and acquisition opportunities to facilitate Gilead’s diversification into new therapeutic areas. She played a lead role in the acquisitions of Corus Pharma ($375M), Myogen ($2.5B) and recently, CV Therapeutics ($1.4B) leading to the establishment of a specialty respiratory and cardiovascular franchises. Shehnaaz has also played a lead role in negotiating tech transfer agreements with Indian generic companies with the goal of facilitating broader access to HIV drugs for patients in the developing world. Prior to Gilead, Shehnaaz was a Healthcare Investment Banker with Lehman Brothers and Vice President at The Petkevich Group, a boutique merchant bank in San Francisco. Shehnaaz is an M.D. who attended the University of Cape Town Medical School and completed a residency in Internal Medicine. Following her residency, she worked in a range of clinical specialties as a Senior House Officer in various hospitals in South Africa and the United Kingdom. Shehnaaz received a Masters degree in Development Studies and an MBA (with distinction) from Oxford University which she attended as a Rhodes Scholar.
Sean OConnell, Senior Director, Business Development, Gilead Sciences
Coming soon!
